文献速递淋巴瘤

PET引导的早期预后良好霍奇金淋巴瘤治疗:HD16试验最终结果

Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group.
PubMed 文献 · J Clin Oncol · 2019-09-10

国际随机III期HD16试验纳入1150例早期预后良好霍奇金淋巴瘤患者,比较标准联合模式治疗(2周期ABVD+20Gy受累野放疗)与PET引导治疗(PET-2阴性者省略放疗)。中位随访45个月,PET-2阴性患者中单纯ABVD的5年PFS为86.1%,联合模式治疗为93.4%,差异7.3%且风险比1.78超过非劣效界值,表明不能安全省略放疗。PET-2阳性(Deauville≥3)是PFS不良风险因素。

要点

  • PET-2阴性早期预后良好HL患者中,省略放疗导致5年PFS绝对下降7.3%,未达非劣效。
  • PET-2阳性(Deauville≥3)是PFS显著不良预后因素,以Deauville 4为界时差异更明显。
  • 联合模式治疗下5年OS两组均约98%,但放疗省略仍造成肿瘤控制损失。

核心结论

  • 在早期预后良好霍奇金淋巴瘤中,2周期ABVD后PET阳性提示治疗失败高风险,尤其以Deauville评分4为阳性界值时。
  • PET-2阴性患者中,省略联合模式治疗中的放疗会导致有临床意义的肿瘤控制丧失。

研究设计与样本

  • 国际随机III期HD16试验由德国霍奇金研究组开展,2009年11月至2015年12月招募18至75岁新诊断早期预后良好HL患者。
  • 患者随机分配至标准联合模式治疗(2×ABVD+20Gy受累野放疗)或PET引导治疗(PET-2阴性者省略放疗)。

主要发现

  • 共纳入1150例患者,中位随访45个月。
  • 628例PET-2阴性符合方案患者中,联合模式治疗5年PFS为93.4%(95%CI 90.4%-96.5%),单纯ABVD为86.1%(95%CI 81.4%-90.9%),差异7.3%(95%CI 1.6%-13.0%),风险比1.78(95%CI 1.02-3.12)。
  • 两组5年OS分别为98.1%(95%CI 96.5%-99.8%)和98.4%(95%CI 96.5%-100.0%)。

关键数值与推荐

  • 非劣效界值:风险比3.01,用于检验单纯ABVD相比联合模式治疗在PET-2阴性患者中5年PFS非劣效(排除10%或以上劣效)。
  • PET-2阳性定义为Deauville评分≥3,但以Deauville评分4为界值时预后区分更显著。

临床怎么用

  • 早期预后良好HL患者接受2周期ABVD后PET-2阴性者,不应省略受累野放疗。
  • PET-2阳性(尤其Deauville评分4)提示治疗失败高风险,可考虑强化治疗或密切监测。

局限性

  • 中位随访仅45个月,长期生存数据尚不成熟。
  • 非劣效性检验仅在PET-2阴性符合方案患者中进行,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Combined-modality treatment (CMT) with 2× ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and small-field radiotherapy is standard of care for patients with early-stage favorable Hodgkin lymphoma (HL). However, the role of radiotherapy has been challenged. Positron emission tomography (PET) after 2× ABVD (PET-2) might help to predict individual outcomes and guide treatment. METHODS: Between November 2009 and December 2015, we recruited patients age 18 to 75 years with newly diagnosed, early-stage favorable HL for this international randomized phase III trial. Patients were assigned to standard CMT of 2× ABVD and 20-Gy involved-field radiotherapy or PET-guided treatment, omitting involved-field radiotherapy after negative PET-2 (Deauville score < 3). Primary objectives were to exclude inferiority of 10% or more in 5-year progression-free survival (PFS) of ABVD alone compared with CMT in a per-protocol analysis among PET-2-negative patients (noninferiority margin for hazard ratio, 3.01) and to confirm PET-2 positivity (Deauville score ≥ 3) as a risk factor for PFS among CMT-treated patients. RESULTS: We enrolled 1,150 patients. Median follow-up was 45 months. Among 628 PET-2-negative, per-protocol-treated patients, 5-year PFS was 93.4% (95% CI, 90.4% to 96.5%) with CMT and 86.1% (95% CI, 81.4% to 90.9%) with ABVD (difference 7.3% [95% CI, 1.6% to 13.0%]; hazard ratio, 1.78 [95% CI, 1.02 to 3.12]). Five-year overall survival was 98.1% (95% CI, 96.5% to 99.8%) with CMT and 98.4% (95% CI, 96.5% to 100.0%) with ABVD. Among 693 patients who were assigned to CMT, 5-year PFS was 93.2% (95% CI, 90.2% to 96.2%) among PET-2-negative patients and 88.4% (95% CI, 84.2% to 92.6%) in PET-2-positive patients (P = .047). When using the more common liver cutoff (Deauville score, 4) for PET-2 positivity, the difference was more pronounced (5-year PFS, 93.1% [95% CI, 90.7% to 95.5%] v 80.9% [95% CI, 72.2% to 89.7%]; P = .0011). CONCLUSION: In early-stage favorable HL, a positive PET after two cycles ABVD indicates a high risk for treatment failure, particularly when a Deauville score of 4 is used as a cutoff for positivity. In PET-2-negative patients, radiotherapy cannot be omitted from CMT without clinically relevant loss of tumor control.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fuchs M, Goergen H, Kobe C, et al. Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019. PMID: 31498753. doi:10.1200/JCO.19.00964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。